125 related articles for article (PubMed ID: 30673073)
1. Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies-Taming T REX.
Damsky W; King BA
JAMA Dermatol; 2019 Mar; 155(3):283-284. PubMed ID: 30673073
[No Abstract] [Full Text] [Related]
2. Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.
Zimmermann N; Wolf C; Schwenke R; Lüth A; Schmidt F; Engel K; Lee-Kirsch MA; Günther C
JAMA Dermatol; 2019 Mar; 155(3):342-346. PubMed ID: 30673078
[TBL] [Abstract][Full Text] [Related]
3. A homozygote TREX1 mutation in two siblings with different phenotypes: Chilblains and cerebral vasculitis.
Kisla Ekinci RM; Balci S; Bisgin A; Altintas DU; Yilmaz M
Eur J Med Genet; 2017 Dec; 60(12):690-694. PubMed ID: 28919362
[TBL] [Abstract][Full Text] [Related]
4. Familial chilblain lupus due to a novel mutation in the exonuclease III domain of 3' repair exonuclease 1 (TREX1).
Günther C; Berndt N; Wolf C; Lee-Kirsch MA
JAMA Dermatol; 2015 Apr; 151(4):426-31. PubMed ID: 25517357
[TBL] [Abstract][Full Text] [Related]
5. Familial chilblain lupus due to a novel mutation in TREX1 associated with Aicardi-Goutie'res syndrome.
Yi C; Li Q; Xiao J
Pediatr Rheumatol Online J; 2020 Apr; 18(1):32. PubMed ID: 32293470
[TBL] [Abstract][Full Text] [Related]
6. Inherited or de novo mutation affecting aspartate 18 of TREX1 results in either familial chilblain lupus or Aicardi-Goutières syndrome.
Tüngler V; Silver RM; Walkenhorst H; Günther C; Lee-Kirsch MA
Br J Dermatol; 2012 Jul; 167(1):212-4. PubMed ID: 22356656
[No Abstract] [Full Text] [Related]
7. A TREX1 mutation causing cerebral vasculopathy in a patient with familial chilblain lupus.
Yamashiro K; Tanaka R; Li Y; Mikasa M; Hattori N
J Neurol; 2013 Oct; 260(10):2653-5. PubMed ID: 23989343
[No Abstract] [Full Text] [Related]
8. Heterozygous TREX1 p.Asp18Asn mutation can cause variable neurological symptoms in a family with Aicardi-Goutieres syndrome/familial chilblain lupus.
Abe J; Izawa K; Nishikomori R; Awaya T; Kawai T; Yasumi T; Hiragi N; Hiragi T; Ohshima Y; Heike T
Rheumatology (Oxford); 2013 Feb; 52(2):406-8. PubMed ID: 22829693
[No Abstract] [Full Text] [Related]
9. A Novel Type I Interferon Primed Dendritic Cell Subpopulation in TREX1 Mutant Chilblain Lupus Patients.
Eugster A; Müller D; Gompf A; Reinhardt S; Lindner A; Ashton M; Zimmermann N; Beissert S; Bonifacio E; Günther C
Front Immunol; 2022; 13():897500. PubMed ID: 35911727
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency.
Briand C; Frémond ML; Bessis D; Carbasse A; Rice GI; Bondet V; Duffy D; Chatenoud L; Blanche S; Crow YJ; Neven B
Ann Rheum Dis; 2019 Mar; 78(3):431-433. PubMed ID: 30282666
[No Abstract] [Full Text] [Related]
11. Human disease phenotypes associated with mutations in TREX1.
Rice GI; Rodero MP; Crow YJ
J Clin Immunol; 2015 Apr; 35(3):235-43. PubMed ID: 25731743
[TBL] [Abstract][Full Text] [Related]
12. Systemic involvement in TREX1-associated familial chilblain lupus.
Günther C; Hillebrand M; Brunk J; Lee-Kirsch MA
J Am Acad Dermatol; 2013 Oct; 69(4):e179-81. PubMed ID: 24034389
[No Abstract] [Full Text] [Related]
13. Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease.
Grieves JL; Fye JM; Harvey S; Grayson JM; Hollis T; Perrino FW
Proc Natl Acad Sci U S A; 2015 Apr; 112(16):5117-22. PubMed ID: 25848017
[TBL] [Abstract][Full Text] [Related]
14. Deregulated type I IFN response in TREX1-associated familial chilblain lupus.
Peschke K; Friebe F; Zimmermann N; Wahlicht T; Schumann T; Achleitner M; Berndt N; Luksch H; Behrendt R; Lee-Kirsch MA; Roers A; Günther C
J Invest Dermatol; 2014 May; 134(5):1456-1459. PubMed ID: 24270665
[No Abstract] [Full Text] [Related]
15. Familial chilblain lupus--a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1.
Günther C; Meurer M; Stein A; Viehweg A; Lee-Kirsch MA
Dermatology; 2009; 219(2):162-6. PubMed ID: 19478477
[TBL] [Abstract][Full Text] [Related]
16. [Familial chilblain lupus : Type 1 interferonopathy with model character].
Fiehn C
Z Rheumatol; 2017 May; 76(4):322-327. PubMed ID: 28389709
[TBL] [Abstract][Full Text] [Related]
17. [Type I interferonopathies].
Munoz J; Marque M; Dandurand M; Meunier L; Crow YJ; Bessis D
Ann Dermatol Venereol; 2015 Nov; 142(11):653-63. PubMed ID: 26363997
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus.
Lee-Kirsch MA; Gong M; Chowdhury D; Senenko L; Engel K; Lee YA; de Silva U; Bailey SL; Witte T; Vyse TJ; Kere J; Pfeiffer C; Harvey S; Wong A; Koskenmies S; Hummel O; Rohde K; Schmidt RE; Dominiczak AF; Gahr M; Hollis T; Perrino FW; Lieberman J; Hübner N
Nat Genet; 2007 Sep; 39(9):1065-7. PubMed ID: 17660818
[TBL] [Abstract][Full Text] [Related]
19. Severe chilblain lupus is associated with heterozygous missense mutations of catalytic amino acids or their adjacent mutations in the exonuclease domains of 3'-repair exonuclease 1.
Sugiura K; Takeichi T; Kono M; Ito Y; Ogawa Y; Muro Y; Akiyama M
J Invest Dermatol; 2012 Dec; 132(12):2855-7. PubMed ID: 22718116
[No Abstract] [Full Text] [Related]
20. Chilblain lupus erythematosus--a review of literature.
Hedrich CM; Fiebig B; Hauck FH; Sallmann S; Hahn G; Pfeiffer C; Heubner G; Lee-Kirsch MA; Gahr M
Clin Rheumatol; 2008 Aug; 27(8):949-54. PubMed ID: 18543054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
